The Best Treatment Approach to Pre-Clinical Diastolic Dysfunction? Think About Exercise Training! by Pressler, Axel et al.
J A C C V O L . 6 4 , N O . 5 , 2 0 1 4 Letters
A U G U S T 5 , 2 0 1 4 : 5 2 8 – 3 0
529be worthwhile to know the calcium–phosphorus
product and intact parathyroid hormone level in the
study population because altered bone mineral
metabolism has been associated with increased car-
diovascular mortality in ESRD patients. Additionally,
the treatment group has a statistically signiﬁcant in-
crease in baseline serum albumin level; improved
nutritional status and decreased protein catabolic
rate may have contributed to reduced cardiovascular
morbidity and mortality in the study cohort.*Arun Kannan, MD
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Approach to Pre-Clinical
Diastolic Dysfunction?
Think About Exercise Training!In their state-of-the-art paper, Wan et al. (1) provide a
comprehensive overview of the assessment, patho-
physiology, and management of pre-clinical diastolic
dysfunction (PDD). This condition has been shown
to represent an early stage in the development of
heart failure with preserved ejection fraction
(HFpEF) and to typically be associated with cardio-
vascular risk factors such as diabetes or hyper-
tension. The authors therefore emphasize that
prevention or treatment of PDD needs to be tailored
to the underlying cardiovascular comorbidities. Very
few studies so far have directly focused on PDD, but
in a variety of recent randomized trials evaluating
different drug treatments in HFpEF, no pharmaco-
logical agent has been shown to consistently improvemarkers, symptoms, or clinical endpoints of this
condition.
Surprisingly, the authors do not report on any
nonpharmacological treatment approaches to PDD
and/or HFpEF, such as exercise training, although
reduced exercise capacity is acknowledged as a hall-
mark of HFpEF. In addition, the aforementioned un-
derlying causes and comorbidities of PDD have all
been shown to be effectively inﬂuenced by regular
exercise. Accordingly, in our multicenter, random-
ized Ex-DHF (Exercise training in Diastolic Heart
Failure) pilot trial evaluating the effects of combined
aerobic and resistance exercise in 64 patients with
HFpEF, we have recently described signiﬁcant in-
creases in exercise capacity and quality of life as
well as signiﬁcant decreases of the E/e0-ratio and
the left atrial volume index as compared with a
nonexercising control group (2). Randomized con-
trolled multicenter studies coheaded by our group are
now underway, evaluating the effects of different
exercise regimens on diastolic function and exercise
capacity in adequately powered cohorts of HFpEF
patients, including the currently highly debated
high-intensity interval training (Ex-DHF, Current
Controlled Trials number ISRCTN86879094; OptimEx
[Optimizing Exercise Training in Prevention and
Treatment of Diastolic Heart Failure], ClinicalTrials.
gov identiﬁer NCT02078947). Certainly, similar to
medical treatment approaches, exercise training will
have to prove signiﬁcant and lasting effects on
the prevention and progression of HFpEF in these
larger trials. However, the aforementioned pre-
liminary, but promising, ﬁndings suggest a clear
lifestyle association that may effectively be reversed
by interventions focusing on exercise training. This
has to be appreciated and included in treatment
recommendations.*Axel Pressler, MD
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to Pre-Clinical Diastolic Dysfunction?:
Think About Exercise Training!We thank Dr. Pressler and colleagues for their interest
in our paper (1). The progression of pre-clinical dia-
stolic dysfunction (PDD) to symptomatic heart failure
with preserved ejection fraction (HFpEF) is depen-
dent on a variety of comorbid conditions, including
pulmonary, renal, and hematologic dysfunction (1).
Because exercise testing may be signiﬁcant in the
diagnosis and prognosis of HFpEF, it follows that
cardiopulmonary rehabilitation may be an important
nonpharmacological intervention.
Edelmann et al. (2) have demonstrated in their
pilot multicenter trial of HFpEF subjects that exercise
improves diastolic function parameters as well as the
outcomes of exercise capacity and quality of life. In
their letter, they emphasize the importance of exer-
cise training for those with diastolic dysfunction.
Cardiac rehabilitation has been shown to have
beneﬁcial effects on symptomatic heart failure as well
as on coronary artery disease. However, its beneﬁt in
patients with stage B or pre-clinical heart failure
remains undeﬁned. Beneﬁts of exercise include, not
only enhanced cardiac function, but also increased
minute ventilation and oxygen utilization, and
improved endothelial, neuroendocrine activity, and
muscle metabolism (3). Because the underlying path-
ophysiology of PDD progression is dependent on
multiple organ systems, cardiopulmonary exercisetherefore may indeed provide, not only diastolic
function beneﬁts, but also pulmonary, hematologic,
and renal beneﬁts as well.
Dr. Pressler and colleagues highlight that an
important aspect of PDD and HFpEF management is
nonpharmacological intervention. In addition to ex-
ercise, other basic nonpharmacological interventions,
such as education, diet, ﬂuid restriction, alcohol and
smoking cessation, and appropriate vaccinations, may
also be important in the cessation of the downward
heart failure spiral (4).
Further studies are needed to better characterize
which of the underlying physiological beneﬁts of
cardiopulmonary exercise directly contribute to the
reduction of heart failure progression, which may
lead to directed exercise activities speciﬁcally to
better target cardiac, pulmonary, or hematologic
dysfunction.Siu-Hin Wan, MD
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